A Balance between R&D and Emerging Markets

Avantika Chilkoti of Financial Times raises a worrying issue in the pharmaceuticals industry: can companies really make up for their R&D expenditures by relying on emerging markets? It is not that easy, apparently. The forecasts made by the companies were not able to predict the real situation in the emerging market countries. Emerging market governments are tend to favour the local economy. Hence it might take time for the big pharmaceuticals to fully integrate into these markets.

Read the full report and analysis at the following link:

EM pharma: a bitter pill to swallow?

Interested in learning more about Asian markets and industries? Do join us at BioPharma Asia Convention 2013 in Resorts World Sentosa, Singapore during March next year to learn more about Asian pharma.

Leave a Reply

Your email address will not be published. Required fields are marked *